What did the transcatheter aortic valve replacement-surgical aortic valve replacement (TAVR-SAVR) trials tell us?

Marvin D. Atkins, Michael J. Reardon

Research output: Contribution to journalArticlepeer-review

Abstract

Two families of randomized trials comparing transcatheter aortic valve replacement (TAVR) to surgery for both the Balloon Expandable Valve and the Supra Annular Self-Expanding Valve have been completed to include all surgical risk levels. The result of these trials has led to the approval of TAVR for symptomatic severe aortic stenosis without using risk level as the sole criterion. We have seen an explosion of TAVR in the US to over 98, 000 commercial cases in 2022. We have also seen a rapid increase in the use of TAVR in patients less than 65 years of age. With these increases, it is important to ask if they are being driven largely by the data or just the desire for TAVR by both patients and their physicians. Heart team input is a class I indication when deciding between TAVR and surgery. For surgical members of the heart team to appropriately counsel patients, a full understanding of what the TAVR surgery trials tell us as well as what they do not is essential. In this article we will explore those questions.

Original languageEnglish (US)
Pages (from-to)206-210
Number of pages5
JournalAnnals of Cardiothoracic Surgery
Volume13
Issue number3
DOIs
StatePublished - 2024

Keywords

  • lifetime management of aortic stenosis (lifetime management of AS)
  • Surgical aortic valve replacement (SAVR)
  • transcatheter aortic valve replacement (TAVR)

ASJC Scopus subject areas

  • Surgery
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'What did the transcatheter aortic valve replacement-surgical aortic valve replacement (TAVR-SAVR) trials tell us?'. Together they form a unique fingerprint.

Cite this